The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
Open accessAbstract
Histone deacetylases (HDACs) represent novel molecular targets for the treatment of various types of cancers, including multiple myeloma (MM). Many HDAC inhibitors have already shown remarkable antitumor activities in the preclinical setting; however, their clinical utility is limited because of unfavorable toxicities associated with their broad range HDAC inhibitory effects. Isoform-selective HDAC inhibition may allow for MM cytotoxicity without attendant side effects. In this study, we demonstrated that HDAC3 knockdown and a small-molecule HDAC3 inhibitor BG45 trigger significant MM cell growth inhibition via apoptosis, evidenced by caspase and poly (ADP-ribose) polymerase cleavage. Importantly, HDAC3 inhibition downregulates phosphorylation (tyrosine 705 and serine 727) of signal transducers and activators of transcription 3 (STAT3). Neither interleukin-6 nor bone marrow stromal cells overcome this inhibitory effect of HDAC3 inhibition on phospho-STAT3 and MM cell growth. Moreover, HDAC3 inhibition also triggers hyperacetylation of STAT3, suggesting crosstalk signaling between phosphorylation and acetylation of STAT3. Importantly, inhibition of HDAC3, but not HDAC1 or 2, significantly enhances bortezomib-induced cytotoxicity. Finally, we confirm that BG45 alone and in combination with bortezomib trigger significant tumor growth inhibition in vivo in a murine xenograft model of human MM. Our results indicate that HDAC3 represents a promising therapeutic target, and validate a prototype novel HDAC3 inhibitor BG45 in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, an example of the importance of the cap group is highlighted in mocetinostat (Figure 10), where selectivity is gained for HDAC1/2 against HDAC3 (5.5–10.7 fold selective) without resorting to the use of an FT substituent [64].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Self-citationHistone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 893
Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
Self-citationSanto, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387365 · Cited by 616
Self-citationHideshima, T., Bradner, J. E., Wong, J. Y. Y., Chauhan, D., Richardson, P. G. G., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 603
Self-citationHideshima, T., Catley, L. P., Yasui, H., Ishitsuka, K., Raje, N. S., Mitsiades, C. S., Podar, K., Munshi, N. C., Chauhan, D., Richardson, P. G. G., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3434 · Cited by 423
Self-citationMolecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature reviews. Cancer · doi:10.1038/nrc952 · Cited by 417
Self-citationCatley, L. P., Weisberg, E., Kiziltepe, T., Tai, Y., Hideshima, T., Neri, P., Tassone, P., Atadja, P. W., Chauhan, D., Munshi, N. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016055 · Cited by 336
Self-citationNonhistone protein acetylation as cancer therapy targets
Singh, B. N., Zhang, G., Hwa, Y. L., Li, J., Dowdy, S. C., & Jiang, S. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.62 · Cited by 315
Flagged first, then by citations
Research works printed but not linked: 1
- Raje N, Mahindra A, Vogl D, Voorhees P, W B, Hari P et al. New drug partner for combination therapy in multiple myeloma (MM): development of ACY-1215, a selective histone deacetylase 6 inhibitor alone and in combination with bortezomib or lenalidomide. Haematologica 2013; 98: 320.
Cited by
Sorted by citations
Items 101–141 of 141
Histone deacetylase‐based dual targeted inhibition in multiple myeloma
Ferro, A., Pantazaka, E., Athanassopoulos, C. M., & Cuendet, M. (2023) · Medicinal Research Reviews · doi:10.1002/med.21972 · Cited by 15
Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies
Patel, P., Shrivastava, S. K., Sharma, P. A., Kurmi, B. D., Shirbhate, E., & Rajak, H. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2192804 · Cited by 12
“HDAC3 is isoenzymes of class I and hopeful therapeutic target which play essential role in the treatment of various types of cancers as well as in multiple myeloma (Cao et al., 2018; Minami et al., 2014; Yan et al., 2018).”
BackgroundMcGee‐Lawrence, M. E., Pierce, J. L., Yu, K., Culpepper, N. R., Bradley, E. W., & Westendorf, J. J. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26148 · Cited by 14
“Hdac3-selective inhibitors, RGFP966 and BG45, have been tested in preclinical models for Huntington's disease (Jia et al., 2012; Wells et al., 2013), and multiple myeloma (Minami et al., 2014) and type I diabetes (Chou et al., 2012).”
BackgroundMDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3
Smalley, J. P., Cowley, S. M., & Hodgkinson, J. T. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00449 · Cited by 12
High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors
Zhao, W., Jiang, X., Weisenthal, K., Ma, J., Botticelli, E. M., Zhou, Y., Hedley‐Whyte, E. T., Wang, B., Swearingen, B., Soberman, R. J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.875122 · Cited by 12
Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice
Baertsch, M., Hillengaß, J., Blocka, J., Schönland, S. O., Hegenbart, U., Goldschmidt, H., & Raab, M. S. (2017) · Hematological Oncology · doi:10.1002/hon.2462 · Cited by 10
“Moreover, HDAC3‐specific inhibitors are currently in preclinical development.(22) In conclusion, we report efficacy of FVD in a heavily pretreated, high‐risk MM patient population refractory to novel agents including”
BackgroundMcEachron, T. A., Kirov, I., Wungwattana, M., Cortés, D., Zabokrtsky, K. B., Sassoon, A., Craig, D. W., Carpten, J., & Sender, L. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25854 · Cited by 10
PML suppresses IL-6-induced STAT3 activation by interfering with STAT3 and HDAC3 interaction
Kato, M., Muromoto, R., Togi, S., Iwakami, M., Kitai, Y., Kon, S., Oritani, K., & Matsuda, T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.040 · Cited by 13
Entinostat-Bortezomib Hybrids against Multiple Myeloma
Ferro, A., Graikioti, D. G., Gezer, E., Athanassopoulos, C., & Cuendet, M. (2023) · Molecules · doi:10.3390/molecules28031456 · Cited by 9
“Furthermore, the combination of the two inhibitors led to cell cycle arrest in G2/M phase and enhanced apoptosis [8,12].”
BackgroundManeix, L., Iakova, P. A., Moree, S. E., Hsu, J. I., Mistry, R. M., Stossi, F., Lulla, P., Sun, Z., Sahin, E., Yellapragada, S. V., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0255 · Cited by 8
Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase
Harada, T., Ohguchi, H., Oda, A., Nakao, M., Teramachi, J., Hiasa, M., Sumitani, R., Oura, M., Sogabe, K., Maruhashi, T., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007155 · Cited by 12
Self-citationDeveloping a Novel Indolocarbazole as Histone Deacetylases Inhibitor against Leukemia Cell Lines
Wang, W.-J., Lv, M., Zhao, X., & Zhang, J.-G. (2015) · Journal of Analytical Methods in Chemistry · doi:10.1155/2015/675053 · Cited by 8
Jha, T., Jana, R., Banerjee, S., Baidya, S. K., Amin, S. A., Gayen, S., Ghosh, B., & Adhikari, N. (2024) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2024.2350504 · Cited by 7
Self-citationCao, G., Yao, S., Li, A., Chen, H., Zhang, E., Cao, L., Zhang, J., Hou, Y., Dai, Z., Chen, J., et al. (2023) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200465 · Cited by 8
Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications
Zhang, B., Chen, D., Dekker, F. J., & Quax, W. J. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.58 · Cited by 6
“BG45 Class I HDAC multiple myeloma([71-73])”
Cyclophilin A as a downstream effector of PI3K/Akt signalling pathway in multiple myeloma cells
Lin, Z.-L., Wu, H.-J., Chen, J., Lin, K., & Hsu, J.-H. (2015) · Cell Biochemistry and Function · doi:10.1002/cbf.3156 · Cited by 7
“HDAC3 inhibition downregulates the activation of STAT3.(33) The Akt kinase is activated in MM tumour cells.”
BackgroundInfluentialGuo, Y., Li, X., He, Z., Ma, D., Zhang, Z., Wang, W., Xiong, J., Kuang, X., & Wang, J. (2020) · Chemotherapy · doi:10.1159/000500713 · Cited by 8
Forestiero, M., Zimbo, A. M., Gentile, G., Puzzo, M., Malivindi, R., Martino, E. A., Vigna, E., Gentile, M., Bonofiglio, D., Gelsomino, L., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07445-8 · Cited by 4
“It has been reported that HDAC3 knock-down in BM MSCs negatively influenced MM cell proliferation through several mechanisms [103].”
van Dijk, A. D., Hoff, F. W., Qiu, Y., Hubner, S. E., Go, R. L., Ruvolo, V. R., Leonti, A. R., Gerbing, R. B., Gamis, A. S., Aplenc, R., et al. (2024) · Cancers · doi:10.3390/cancers16081448 · Cited by 4
“For example, in multiple myeloma, bortezomib enhances apoptosis through targeting HDACs [12], predominantly through the downregulation of HDAC3 [46].”
BackgroundChitti, S., Pulya, S., Nandikolla, A., Patel, T., Banoth, K. K., Murugesan, S., Ghosh, B., & Kondapalli, V. G. C. S. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0237 · Cited by 4
Self-citationDeciphering epigenetic crosstalk in multiple myeloma pathogenesis and treatment
Alipoor, S. D., Shrestha, M., Liu, A., & Chang, H. (2026) · Clinical Epigenetics · doi:10.1186/s13148-026-02109-w · Cited by 3
“Dysregulated HDAC activity in MM fosters tumor cell proliferation and resistance to therapy, with specific isoforms such as HDAC3 and HDAC6 implicated in survival signaling, protein degradation pathways [62], and modulation of the BME [57].”
Li, H., Zhao, Y.-X., Niu, J.-B., Song, J. H., & Zhang, S. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112263 · Cited by 3
EPAS1 increases SDHA to inhibit proliferation of multiple myeloma cells by restoring TCA Cycle
Sun, Y., Maihemaiti, A., Zhao, X., Tang, L., Wang, Y., Jiang, J., Zhou, H. J., Pan, C., Pang, Y., & Liu, P. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01194-z · Cited by 2
Zhang, Q., Sun, W., Zheng, M., Wang, Q.-P., Liu, G., Li, L.-J., Zhang, R.-Y., & Zhang, N. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106256 · Cited by 3
Gu, Z., Liu, Y.-C., Jiao, Y., Wang, H., Wang, L., Le, N., Zhang, X.-W., Liu, Q.-Y., Xu, Y., Liu, D.-H., et al. (2025) · medRxiv · doi:10.3389/fimmu.2026.1752727 · Cited by 2
“Like the role of HDAC3 reported in multiple myeloma and cutaneous T-cell lymphoma (43, 44), our study demonstrated that knockdown or pharmacological inhibition of HDAC3 inhibited the growth of T-ALL cells and induced apoptosis and cell cycle arrest.”
Maji, A., Himaja, A., Nikhitha, S., Rana, S., Paul, A., Samanta, A., Shee, U., Mukhopadhyay, C., Ghosh, B., & Maity, T. K. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00279b · Cited by 6
Self-citationHDAC2: a potential target for neurological diseases
Peng, S.-Y., & Yuan, Z.-Q. (2015) · Therapeutic Targets for Neurological Diseases · doi:10.14800/ttnd.723 · Cited by 2
Liu, J.-Y., Quan, Y., Wang, Y.-L., Nie, W.-Z., Cui, C.-M., Zhao, B., Cui, N.-N., Lian, Q.-B., Li, G., & Shen, Q. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118697 · Cited by 1
Holstein, S. A., Asimakopoulos, F. A., Azab, A. K., Bianchi, G., Bhutani, M., Crews, L. A., Cupedo, T., Giles, H. V., Gooding, S., Hillengaß, J., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.019 · Cited by 1
Histone Modifying Enzymes as Targets for Therapeutic Intervention in Oesophageal Adenocarcinoma
Pickering, O. J., Breininger, S. P., Underwood, T., & Walters, Z. S. (2021) · Cancers · doi:10.3390/cancers13164084 · Cited by 2
“Romidepsin, an HDAC1 and HDAC2 inhibitor, was the first to be approved by the FDA for treatment of CTCL and PTCL [26] and there are promising results seen in pre-clinical trials for inhibitors of HDAC3 [61], 4 [62], 5 [63] and 8 [64] in various cancer types.”
BackgroundHistone deacetylase inhibitors in multiple myeloma.
Pratt, G. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70425-x · Cited by 1
Zhang, K., Liu, J., Bi, J., Lin, S., Wu, D., Li, S., Ning, Q., Sheng, L., Ge, J. U. N. B. O., Xu, H., et al. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.112995
Desaminotyrosine promotes tuft cell expansion and integrates intestinal type 2 immunity
Zang, W., Zhou, Z., Shen, Y., Zhang, B., Chen, X., Yue, W., Li, X., Cai, Y., Chen, J., Bian, J., et al. (2026) · mBio · doi:10.1128/mbio.03289-25
“RGFP966 is a highly selective HDAC3 inhibitor and shows no inhibition to other HDACs (25).”
Muhsin, A., Neja, S., Mohan, N., Kapoor, S., Perez, J. E. T., Dashwood, W., Rashid, A., Dashwood, R. H., & Rajendran, P. (2025) · Journal of Cancer Prevention · doi:10.15430/jcp.25.016
Wei, D.-N., Liang, X.-L., Huang, M., Wang, C.-L., Ye, Z., Zhang, T.-Z., & Zhang, J.-R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05830-9
“It has been demonstrated that HDACs regulate the proliferation of leukemia cells both alone and co-culture with BMSCs [23, 24].”
Analysis of the Bach2 and HDAC3 Expression in Iranian Patients with Acute Myeloid Leukemia
Safari, I., Nourian, M., Naghoosi, H., Etemadi, A., Zeinali, F., Jalaeikhoo, H., & Rajaeinejad, M. (2019) · International Journal of Cancer Management · doi:10.5812/ijcm.91545
Targeting (de)acetylation: A Diversity of Mechanism and Disease
Quaas, C. E., & Long, D. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00076-1
Choudhury, S. R., & Walker, B. A. (2019) · RNA technologies · doi:10.1007/978-3-030-14792-1_22 · Cited by 1
Epigenetische Strategien in der Krebstherapie
Heßmann, E., Johnsen, S. A., & Ellenrieder, V. (2017) · best practice onkologie · doi:10.1007/s11654-017-0006-1
“Zahlreiche präklinische Daten charakterisieren die Familie der HDAC-Proteine als zentrale Mediatoren des Tumorzellwachstums und -überlebens [14, 17, 19].”
BackgroundEpigenetische Strategien in der Krebstherapie
Heßmann, E., Johnsen, S. A., & Ellenrieder, V. (2015) · Der Onkologe · doi:10.1007/s00761-015-2998-x
Metadata
- Authors
- Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., Jakubikova, J., Munshi, N. C., Haggarty, S. J., Richardson, P. G., Hideshima, T., & Anderson, K. C.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Anderson, K C
- ORCID
- Venue
- Leukemia
- Published
- 2013-08-05
- Volume
- 28
- Issue
- 3
- Pages
- 680-689
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC4165599
- OpenAlex
- W2004288940
- Cited by
- 159
- References
- 37
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 15 · 2021: 10 · 2020: 15 · 2019: 13 · 2018: 14 · 2017: 16 · 2016: 6 · 2015: 18 · 2014: 8 · 2013: 3
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p01ca078378-15, 5r01ca178264-05)
- U.S. Public Health Service (P50100707)
- National Institute on Drug Abuse (R01 DA02830)
- National Cancer Institute (R01-CA178264, P01-CA-78378, P50CA086355, R01- CA50947, P01-CA078378, P50CA100707, R01CA050947, P01CA155258)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Keywords
- HDAC3, multiple myeloma, HDAC3 inhibitors, STAT3 phosphorylation, STAT3 acetylation, bortezomib combination therapy, apoptosis, caspase activation, poly(ADP-ribose) polymerase, interleukin-6, mesenchymal stem cells, HDAC isoform selectivity, tumor growth inhibition
- MeSH terms
- Histone Deacetylase 3, Cell Division, Histone Deacetylases, Humans, Multiple Myeloma, Cell Line, Tumor, Gene Knockdown Techniques, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
